Issue 10, 2025, Issue in Progress

Green synthesis of new adamantane-containing dihydropyrimidine derivatives as potential anticancer agents

Abstract

Despite significant progress in cancer treatment, cancer remains a major focus of research due to medication resistance and side effects. In this study, bioactive adamantane-containing dihydropyrimidine (DHPM) derivatives were synthesized through the multi-component Biginelli reaction of N-(adamant-1-yl)acetoacetamide, benzaldehyde derivatives, and thiourea in the presence of trifluoroacetic acid (TFA, 2 mol%) as catalyst under solvent free conditions. This method provides an effective and significantly improved modification of the original Biginelli reaction in terms of yield and reaction time. The synthesized DHPM derivatives were subjected to cytotoxicity screening against the A-549 human non-small cell lung cancer (NSCLC) cell line to evaluate their effects on cell growth inhibition. MTT cytotoxicity assay was used to determine IC50 values. Among the target analogs, IIb, IIj, IId, and IIg demonstrated the best activity with IC50 values of 1.03, 8.36, 10.38, and 16.04 μg mL−1, respectively. Additionally, we assessed the possible mechanisms for cell growth inhibition and induction of apoptotic cell death using the DAPI and Annexin V-FITC staining. The average percentages of apoptotic cells were 21.35%, 28.35%, 32.73, and 43.33% for IIg, IId, IIj, and IIb treatment groups, respectively. These results suggest that the synthesized adamantane-containing dihydropyrimidines can be considered as encouraging molecules for further drug development as anticancer agents.

Graphical abstract: Green synthesis of new adamantane-containing dihydropyrimidine derivatives as potential anticancer agents

Supplementary files

Article information

Article type
Paper
Submitted
12 Jan 2025
Accepted
06 Mar 2025
First published
13 Mar 2025
This article is Open Access
Creative Commons BY license

RSC Adv., 2025,15, 7949-7955

Green synthesis of new adamantane-containing dihydropyrimidine derivatives as potential anticancer agents

A. Moshtaghi Zonouz, M. Abkar Aras, N. Jafari, Z. Rezaei and H. Hamishehkar, RSC Adv., 2025, 15, 7949 DOI: 10.1039/D5RA00284B

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements